Suscribirse

Development and validation of a model for predicting 18-month mortality in type 2 myocardial infarction - 09/10/21

Doi : 10.1016/j.ajem.2021.04.060 
Truong H. Hoang, MD, PhD a, , Victor V. Maiskov, MD, PhD a, b, Imad A. Merai, MD, PhD a, b, Zhanna D. Kobalava, MD, DMedSc a
a Department of Internal Diseases with the Course of Cardiology and Functional Diagnostics named after V.S. Moiseev, Institute of Medicine, RUDN University, Moscow, Russia 
b Vinogradov City Clinical Hospital, Moscow, Russia 

Corresponding author at: Department of Internal Diseases with the Course of Cardiology and Functional Diagnostics named after V.S. Moiseev, Institute of Medicine, RUDN University, 117198, Miklukho-Maklaya Street, 6, Moscow, Russia.Department of Internal Diseases with the Course of Cardiology and Functional Diagnostics named after V.S. MoiseevInstitute of MedicineRUDN University117198, Miklukho-Maklaya Street, 6MoscowRussia

Abstract

Background

Despite the poor prognosis in patients with type 2 myocardial infarction (MI), no prospective data on risk stratification exists. The aim of this study was to develop and validate a model for prediction of 18-month mortality of among patients with type 2 MI (T2MI) and compare its performance with GRACE and TARRACO scores.

Methods

The prospective observational study included 712 consecutive patients diagnosed with MI undergoing coronary angiography <24 h between January 2017 and December 2018. Diagnosis of T2MI was adjusted according to Third universal definition. A prognostic model was developed by using Bayesian approach and logistic regression analysis with identifying predictors for mortality. The model was validated by bootstrap validation. Comparison performance between scores using Delong test.

Results

T2MI was identified in 174 (24.4%) patients. The median age of patients was 69 years, 52% were female. The mortality rate was 20.1% at 18 months. Prior MI, presence of ST elevation, hemoglobin level at admission, Charlson comorbidity index and were independently associated with 18-month mortality. The model to predict 18-month mortality showed excellent discrimination (optimism corrected c-statistic = 0.822) and calibration (corrected slope = 0.893). GRACE and TARRACO scores had moderate discrimination [c-statistic = 0.748 (95% CI 0.652–0.843) and 0.741, 95% CI 0.669–0.805), respectively] and inferior compared with model (p = 0.043 and 0.037, respectively).

Conclusions

The risk of mortality among T2MI patients could be accurately predicted by using common clinical characteristics and laboratory tests. Further studies are required with external validation of nomogram prior to clinical implementation.

El texto completo de este artículo está disponible en PDF.

Highlights

Modest performance of GRACE (AUC = 0.748) and TARRACO (AUC = 0.741) scores for 18-month mortality in type 2 MI.
Developed 18-month mortality model in type 2 MI included 4 factors: prior MI, ST elevation, hemoglobin level, comorbidity.
Model discrimination (AUC = 0.840, after bootstrapping corrected AUC= 0.822) and calibration (corrected slope = 0.893).
Model’s performance was surpassed GRACE (p = 0.043) and TARRACO (p = 0.037) scores for 18-month mortality in type 2 MI.

El texto completo de este artículo está disponible en PDF.

Keywords : Type 2 myocardial infarction, Prognostic model, Mortality


Esquema


© 2021  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 48

P. 224-230 - octobre 2021 Regresar al número
Artículo precedente Artículo precedente
  • Criticality index conducted in pediatric emergency department triage
  • Theodore W. Heyming, Chloe Knudsen-Robbins, William Feaster, Louis Ehwerhemuepha
| Artículo siguiente Artículo siguiente
  • The impact of emergency department observation units on a health system
  • Michael Perry, Nicole Franks, Stephen R. Pitts, Tim P. Moran, Anwar Osborne, Dane Peterson, Michael A. Ross

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.